Review

Getting to grips with sarcopenia: recent advances and practical management for the gastroenterologist

Thomas William Hollingworth,1 Siddhartha M Oke,2 Harnish Patel,3 Trevor R Smith1

1Department of Gastroenterology, University Hospital Southampton NHS Foundation Trust, Southampton, UK
2Department of Gastroenterology, Saint Mark’s Hospital, Harrow, UK
3Geriatrics, University Hospital Southampton NHS Foundation Trust, Southampton, UK

Correspondence to
Dr Thomas William Hollingworth,
Department of Gastroenterology,
University Hospital Southampton
NHS Foundation Trust,
Southampton, Hampshire SO16 6YD, UK;
Thomas.Hollingworth@UHS.nhs.uk

Received 13 October 2019
Revised 27 December 2019
Accepted 30 December 2019
Published Online First
20 January 2020

Sarcopenia is a progressive and generalised disorder of skeletal muscle strength, function and mass, that is most commonly associated with the normal ageing process. It is increasingly recognised that sarcopenia can also develop as a consequence of malabsorptive and inflammatory conditions, such as those seen by gastroenterologists and hepatologists. It affects 1%–30% of the general population, but is seen in approximately 40% of patients with gastrointestinal conditions including inflammatory bowel disease and cirrhosis. Within this group of patients, it is associated with increased complications and mortality. The pathogenesis of sarcopenia is multifactorial with several risk factors implicated in its development including undernutrition, physical inactivity and coexistent multimorbidity. The SARC-F questionnaire has been developed to screen for patients at risk of sarcopenia, however, this focuses on the functional consequences and will therefore not identify those patients who are early in the progression of sarcopenia. There are several different non-invasive techniques available to assess muscle quantity and quality including; grip strength, dual energy X-ray absorptiometry, CT which can be used together to diagnose sarcopenia. Assessment and correction of malnutrition, particularly protein intake, in those at risk of sarcopenia is important in preventing the development and progression of sarcopenia. There are no specific drugs that are available for the treatment of sarcopenia, however, resistance exercise programmes combined with nutritional supplementation have shown promise.

INTRODUCTION

The sixth age shifts
Into the lean and slipper’d pantaloon
With spectacles on nose and pouch on side,
His youthful hose well sav’d, a world to wide,
For his shrunk shank
Shakespeare, As You Like It, Act II, Scene VII, lines 157–161

Skeletal muscle is an extraordinary, plastic tissue critical not only for locomotion and thermoregulation but also for metabolic homeostasis, accounting for approximately 40% of total body mass.2 The association between the ageing process
and muscle loss was first recognised by Critchley in 1931; noting a decline of lean body mass, with early signs being most noticeable in the intrinsic muscles of the hands and feet.3 The term sarcopenia, derived from the Greek words Sarx and penia, translated as poverty of flesh, was first used to describe this condition by Rosenberg in 1989, recognising that ‘there may be no single feature of age related decline more striking than the decline in lean body mass in affecting ambulation, ability, energy intake and status, independence and breathing’.4 Sarcopenia is now widely recognised as muscle failure consequent to loss of skeletal muscle strength, function and mass.

While primary sarcopenia is considered part of the normal ageing process, nicely illustrated by the decline in the total weight lifted at the masters weightlifting championships with increasing age (figure 1), secondary sarcopenia has been described in conditions that are not solely a consequence of the ageing process, such as malabsorptive conditions, immobility/bed rest, starvation, hypothyroidism and a number of inflammatory conditions, that may be encountered in clinical practice5 (figure 2). There is also recognition that sarcopenia can be an acute phenomenon, lasting less than 6 months, associated with an acute illness or injury. Both primary and secondary sarcopenia are associated with a broad range of adverse outcomes such as functional decline, falls, fractures, hospitalisation and increased hospital length of stay.6 A recent meta-analysis which included community dwelling, nursing home and hospitalised patients over the age of 60, suggested a higher mortality OR (3.60) in individuals with sarcopenia; with those over 79 being at greatest risk.6 Furthermore, this systematic review and meta-analysis showed that the rate of functional decline, rate of falls and hospital admissions was higher in those who were sarcopenic. Sarcopenia is also associated with high personal, social and economic burden when left unrecongised and untreated, including disability, loss of independence and poor quality of life. Sarcopenia therefore represents a major health problem for men and women across all medical and surgical specialties especially in context of global demographic changes.

In gastroenterology and hepatology patients, the development of sarcopenia is associated with; undernutrition, inflammatory bowel disease (IBD),7 8 liver disease9 and intestinal failure (IF).10 It is associated with increased complications9 11–14 and increased mortality.15 By proactively diagnosing and treating sarcopenia the clinical course for these patients can be significantly improved.

DEFINING SARCOPEANIA

There are no universally accepted diagnostic criteria for sarcopenia. Consensus definitions have been produced by the European Working Group on Sarcopenia in Older People 2 (EWGSOP2),16 the International Working Group on Sarcopenia 17 and the Asian Working Group for Sarcopenia 18 which all include the measurement of muscle strength, muscle mass and physical performance, for example, through hand grip strength measurement, appendicular lean mass index (ALMi) and gait speed measurement16 18 (table 1). The consensus definition produced by the EWGSOP2 was updated in 2018 using these measures16 (figure 3).

The Foundation for the National Institutes of Health consortium has used regression tree analysis in pooled data from several studies, concluding that a combination of grip strength and ALM adjusted for body mass index (BMI) and gait speed measurement16 18 (table 1). The consensus definition produced by the EWGSOP2 was updated in 2018 using these measures16 (figure 3). The Foundation for the National Institutes of Health consortium has used regression tree analysis in pooled data from several studies, concluding that a combination of grip strength and ALM adjusted for body mass index (BMI) were the most reliable way of demonstrating the presence or absence of sarcopenia.19 An operational definition is needed to allow development and evaluation of interventions for prevention and treatment, and with the emergence of a number of candidate therapies, this has become more pressing.7
Table 1  Definition of sarcopenia by different groups
Society                         | Definition                                      | Cut-off point
---                             | ---                                            | ---
European Working Group on Sarcopenia in Older People 16 | Low ASMI adjusted for height And either Gait speed OR Grip strength | Men <7.0 kg/m² Women ≤6.0 kg/m² Women <7.23 kg/m² Men <27 kg Women ≤5.67 kg/m² Men <20 kg Women ≤18 kg
International Working Group on Sarcopenia 17          | Low ASMI adjusted for height And either Gait speed OR Grip strength | Men <7.0 kg/m² Women ≤5.4 kg/m² Men <7.0 kg/m² Women ≤5.67 kg/m² Men <27 kg Women ≤5.4 kg/m² Women ≤7.23 kg/m² Men ≤16 kg Women ≤7.0 kg/m²
Asian Working Group for Sarcopenia 18                  | Low ASMI adjusted for height And either Gait speed OR Grip strength | Men <7.0 kg/m² Women ≤5.4 kg/m² Men <27 kg Women ≤5.4 kg/m² Men <16 kg Women ≤5.4 kg/m² Women ≤16 kg

ASMI, appendicular skeletal muscle index.

EPIDEMIOLOGY
The prevalence of sarcopenia in the population varies widely in the published literature. This is likely to be a result of a heterogeneity of the criteria used for the diagnosis of sarcopenia including; different modalities for assessing muscle mass and function as well as different populations studied. In people over the age of 60, the reported prevalence ranges between 1% and 30%. The prevalence increases with advancing age, one study reported that 7%–10% of people aged between 60 and 70 years were sarcopenic while 30% of those over 80 years of age were sarcopenic.17

SARCOPENIC OBESEITY, CACHEXIA AND FRAILTY: CLINICALLY DISTINCT BUT OVERLAPPING CONDITIONS
Sarcopenic obesity is a separate condition characterised by reduced muscle mass in the context of increased adiposity. In addition to reduced muscle mass, excess adiposity also has a detrimental effect on muscle function and quality as a result of increased infiltration of fat into the muscle itself.16 Sarcopenic obesity is associated with disability, gait problems and falls to a greater extent than persons with ‘proportionate’ sarcopenia.17 In conditions such as malignancy, rheumatoid arthritis and ageing, lean body mass is lost while fat mass may be preserved or even increased.21 Fat is considered proinflammatory and may drive muscle catabolism in his regard.

Cachexia is a multifactorial condition characterised by severe body weight, fat and muscle loss. It occurs as a consequence of underlying illness, primarily driven by a marked inflammatory response.23 While the loss of muscle mass is also a feature of cachexia, most sarcopenic patients are not always cachectic.5 Frailty is a common clinical syndrome in which multiple body systems lose their reserves which can lead to weakness and poor functional capacity.24 Frailty is a state of physiological vulnerability driven by disruption of homoeostatic mechanisms in one or more systems for example, neurological, brain, endocrine as well as skeletal muscle as well as the occurrence of adverse events in the social and psychological domains that comprise the frailty syndrome. Sarcopenia is a core component of physical frailty domain and was well described in the seminal paper by Fried et al.25

PATHOPHYSIOLOGY
The pathogenesis of sarcopenia is multifactorial with several risk factors implicated in its development including undernutrition, physical inactivity and coexistent multimorbidity. Early fetal development also has important roles in the development of sarcopenia, with several birth cohort studies reporting a strong association between low birth weight and low hand grip strength and peak muscle mass.26–28 Cell and molecular consequences include an imbalance in muscle protein turnover, chronic inflammation, oxidative stress/mitochondrial dysfunction.29

Muscle mass is a function of muscle fibre (myofibre) number and cross sectional area.30 Cross-sectional and longitudinal studies have shown that muscle mass starts to decline in the fourth decade and progresses at a rate of 0.5%–1% a year with a more precipitous drop after the eighth decade.31 Muscle force is also impaired in parallel but not in direct proportion to
the loss of muscle mass. The age-related loss of human skeletal muscle mass occurs through atrophy and loss of both myofibre type with greater preponderance in type II fibres; leading, through an imbalance of muscle protein synthesis and breakdown, fatty deposition and infiltration of non-contractile proteins, to a decreased muscle quality and function.\(^{31}\)

The most completely understood pathway for muscle turnover involves activation of serine/threonine kinase which amplifies mammalian target of rapamycin leading to increased muscle protein synthesis. This pathway is upregulated by anabolic stimuli such as insulin-like growth factor-1 (IGF-1), testosterone and exercise.\(^{32}\) Testosterone is also implicated in the repair of myocytes through stimulation of myoblasts and inhibition of myostatin. Reductions in the levels of both IBD and liver disease. Studies estimate that undernutrition affects 65%–75% of patients with Crohn’s disease, 18%–62% of patients with ulcerative colitis\(^8\) and 50%–90% of patients with cirrhosis.\(^9\)

A 2017 systematic review reported that 41.6% of patients with IBD had sarcopenia.\(^7\) Interestingly, one study noted that 40% of sarcopenic patients with IBD had a normal BMI, with 20% overweight or obese. Studies have tried to identify risk factors for the development of sarcopenia in IBD which include BMI, ALMi measured by dual energy X-ray absorptiometry (DXA), C-reactive protein, disease duration and body fat percentage.\(^{34}\) Three studies have been performed to look at the association between sarcopenia in IBD and the risk of requiring surgery and surgical outcomes. These studies have reported that sarcopenic IBD patients have a higher risk of requiring surgery, particularly colectomy when compared with the non-sarcopenic IBD population.\(^{12,13,37}\) In one study, this effect was most pronounced in the obese, sarcopenic IBD patients.\(^{38}\) Two studies have shown a positive association between sarcopenia in the IBD patient and the prevalence of postoperative complications.\(^{37,39}\) In subgroup analysis it was found to be significantly associated with postoperative sepsis, increased length of hospital stay, deep vein thrombosis and admission to the intensive care unit.\(^{39}\)

There is little published research on the incidence of sarcopenia in liver disease, with two studies reporting it being present in approximately 40% of patients.\(^9\) Prospective studies have shown that undernutrition and sarcopenia are independent risk factors for variceal bleeding and mortality in these patients.\(^4\) The median survival for patients assessed for liver transplantation in one centre was reported as 34 months in non-sarcopenic patients compared with 19 months in sarcopenic patients. This was as a consequence of a significantly higher incidence of sepsis-related deaths in the sarcopenic group.\(^{15}\) Furthermore, skeletal muscle plays a significant role in ammonia detoxification placing sarcopenic, cirrhotic patients at a higher risk of developing hepatic encephalopathy.\(^9\)

Sarcopenia is an increasingly recognised phenomena in patients with IF. To date, data on prevalence are limited, with the largest recent study demonstrating a prevalence of 72.7% in patients with IF.\(^10\)

**SCREENING**

The EWGSOP2 recommend screening for sarcopenia prior to measuring muscle strength (figure 2). The SARC-F questionnaire has been developed to identify those at risk of sarcopenia by assessing their functional capacity in everyday activities.\(^{40,41}\) This simple questionnaire assesses the difficulties a patient has in performing everyday tasks including; carrying heavy loads, walking, transferring from chair to bed, climbing stairs as well as the number of falls in the past year, with a score of 0, 1 or 2 assigned to each category. A score of ≥4 suggests evidence of symptomatic sarcopenia (table 2).
be used in those who are unable to use a dynamometer, such as the chair stand test. This measures the amount of time it takes a patient to rise from sitting five times as an assessment of the strength of proximal leg muscles.

### Measuring muscle mass and quantity

There are several different non-invasive imaging techniques available to assess muscle quantity including appendicular skeletal muscle index (ASMI) via DXA, CT, MRI or ultrasound. ASMI measured by DXA is currently the most favoured modality for quantifying muscle quantity.\(^{50}\) DXA scanners emit X-ray photons at two energy levels, the ratio of the attenuation of these two energy levels allows for an estimation of soft tissue mass in relation to body size. From this further extrapolations can be made to calculate lean mass, fat mass and muscle mass and from there appendicular skeletal mass,\(^{31}\) which is used in the study of sarcopenia. The advantages of DXA are that it has low radiation doses, it is quick and non-invasive with reproducible results, when the same equipment is used. There are however differences in results between different DXA instrument brands and it is not portable, limiting use in the community.

CT and MRI have long been considered the gold standard for the non-invasive assessment of muscle quantity as well as quality in the entire body. This process can be time consuming and therefore a method of calculating of skeletal muscle mass using a CT image taken at the level of the third lumbar vertebra (L3) (LSMI) has been developed and validated. This measures the total muscle mass formed from the psoas, paraspinal muscles and abdominal wall, standardising the total surface area for height to form the L3 muscle index (total muscle surface area (cm\(^2\))/height squared (m\(^2\)), providing an estimation of total skeletal body muscle.\(^{52}\) This method has the advantage of being very accurate, with reproducible results and can be taken from a CT or MRI taken for another purpose. It has been used to detect low muscle mass, predicting mortality in cancer patients\(^{53,54}\) or outcomes in the intensive care unit.\(^{55}\) It does, however, expose patients to ionising radiation limiting its use in sequential measurements to assess response to treatment. This is in addition to the high equipment costs, lack of portability and requirement for highly trained clinicians to assess the imaging. Muscle ultrasound is widely used within the research community as the sensitivity and quality of muscle by measuring muscle thickness, cross-sectional area, fascicle length, pennation angle and echogenicity.\(^{56}\)

Bio-impedance (BIA) has long been used to estimate ASMI through the measurement of whole-body electrical conductivity. The principle behind BIA is that current is well conducted by water, blood and muscle and poorly by fat, air-filled spaces and bone. In order to estimate whole body composition, electrodes are placed in a tetrapolar arrangement on both hands and

<table>
<thead>
<tr>
<th>Component</th>
<th>Question</th>
<th>Scoring</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strength</td>
<td>How much difficulty do you have in lifting and carrying 10 pounds?</td>
<td>None=0, Some=1, A lot or unable=2</td>
</tr>
<tr>
<td>Assistance in walking</td>
<td>How much difficulty do you have walking across a room?</td>
<td>None=0, Some=1, A lot, use aids or unable=2</td>
</tr>
<tr>
<td>Rise from chair</td>
<td>How much difficulty do you have transferring from a chair to a bed?</td>
<td>None=0, Some=1, A lot or unable without help=2</td>
</tr>
<tr>
<td>Climb stairs</td>
<td>How much difficulty do you have climbing a flight of ten stairs?</td>
<td>None=0, Some=1, A lot or unable=2</td>
</tr>
<tr>
<td>Falls</td>
<td>How many times have you fallen in the last year?</td>
<td>None=0, 1–3 falls=1, 4 or more falls=2</td>
</tr>
</tbody>
</table>

A score ≥4 is considered to be evidence of symptomatic sarcopenia.

While SARC-F has been validated in several international cohorts of older patients\(^{43,44}\) with excellent specificity (98.1%), it has poor sensitivity (29.5%) for sarcopenia.\(^{45}\) Furthermore, this screening tool only identifies those who have functional consequences of sarcopenia and will therefore do not identify those patients who are early in the progression of sarcopenia or those who are able to compensate for their sarcopenia. Attempts have been made to simplify and refine SARC-F with a consequent reduction in sensitivity and specificity.\(^{45}\) An additional screening tool is available in the form of the Ishii screening test which estimates the probability of sarcopenia based on age, grip strength and calf circumference\(^{44}\) with studies showing a specificity of 84.3%–100% and sensitivity of 74.3%–80.9%, depending on the definition of sarcopenia used.\(^{45}\)

#### ASSESSMENT OF SARCOPENIA

The EWGSOP2 diagnostic algorithm recommends ascertainment of muscle strength followed by either intervention if sarcopenia is suspected or follow-up by measurement of muscle mass and physical performance (figure 3). There are many different tools available for the assessment of sarcopenia which assess muscle strength and quantity. In the past there has been a lack of gold-standard techniques for the diagnosis of sarcopenia due to a lack of agreement of the definition of sarcopenia and hard end points for intervention.

#### Measuring muscle strength

The measurement of grip strength is an inexpensive and simple tool available using a calibrated handheld dynamometer.\(^{46}\) Measurements of grip strength correlate well with the strength of other muscle compartments with good reliability and reproducibility. This ease, reliability and availability has led to its recommendation for use in both hospital and community settings\(^{47,49}\) (table 1). Surrogate assessments can also

Small bowel and nutrition

feet. The impedance is calculated by a vector calculation which takes into account the resistance and reactance of the current in combination with a phase angle (created from the capacitance of the tissue). BIA has advantages of being safe, inexpensive with portable equipment that is rapid to use. It does however have several problems, the first of which is that the readings obtained are algorithmic calculations based on assumptions of the standard body composition. In certain disease states where both composition and body geometry are altered the accuracy of this technique is therefore brought into question.

INTERVENTIONS

The EWGSOP2 algorithm recommends early intervention in all patients with suspected sarcopenia after the measurement of grip strength (figure 3). Studies have looked at several different interventions to improve muscle mass, quality and function in patients with sarcopenia; including exercise interventions to improve muscle strength and physical performance, nutritional supplementation to improve muscle protein synthesis and pharmacological agents to reduce muscle turnover.

Nutritional interventions

There is a significant decline in food and energy intake with increasing age and associated with many chronic diseases associated with sarcopenia. There have therefore been a significant number of studies assessing the effect of nutritional supplementation, particularly; protein, vitamin D, amino acid, beta-hydroxy-beta-methylbutyrate (HMB) and fatty acids on sarcopenia.

Dietary protein provides essential amino acids for the synthesis of muscle protein, in addition to providing an anabolic stimulus that increases muscle protein synthesis. The body is unable to store unused protein for periods of catabolic stress, such as hospitalisation or illness, instead relying on skeletal muscle as a reservoir. This is even more crucial in patients with malabsorptive or other gastroentrological problems that limit their nutrition intake. If adequate protein consumption is not maintained, skeletal muscle amino acids are released during these periods of stress leading to muscle atrophy, impaired muscle function and growth. (National Institute for Health and Care Excellence (NICE) guidelines suggest that well patients require 0.8–1.5 g of protein per kg per day. The PROT-AGE study has subsequently calculated that the optimal dietary intake of protein is between 1 and 1.2 g of protein per kg per day, with 1.2–1.5 g/kg/day required, when combined with exercise to maintain function. It is important to recognise those patients who are unable to meet these requirements or are already malnourished, using screening tools such as a Malnutrition Universal Screening Tool (MUST) score. In these patients a dietary assessment is important to assess and maximise their nutritional intake or provide nutritional support. Commonly simple interventions, such as the provision of oral nutritional supplements would provide 12 g of protein, 300 kcal, in addition to a full range of vitamins and minerals.

One study has been performed that has highlighted the benefits of adequate nutrition and protein supplementation in 114 sarcopenic IBD patients undergoing surgery for disease management. In this study, patients receiving preoperative enteral or parenteral nutrition had a significant reduction in major postoperative complications when compared with those that had not (6.5% vs 28.6%). The effect of protein supplementation on muscle mass and functional capacity has been assessed in five studies, of these only one study did not include an exercise programme. While the remaining three studies supplemented participants normal diet with between 30 and 40 g of protein a day in divided doses over a period of 24 weeks to 18 months. All of these studies showed no improvement in muscle strength nor physical performance. There are no studies that assess the use of parenteral nutrition in the treatment of sarcopenia, however, a recent study has reported a significant improvement in LSMI, but not anthropometric measurements following the provision of parenteral nutrition.

Vitamin D deficiency is commonly found in both sarcopenic patients and those with gastrointestinal disorders. Studies have reported a prevalence of 70% in Crohn’s disease, 40% in ulcerative colitis (UC) and 64%–92% in cirrhosis. It has been postulated that vitamin D deficiency can accelerate sarcopenia with epidemiological evidence that normalisation of vitamin D levels can prevent falls indicating an improvement in functional capacity. No studies have been performed that look at vitamin D and sarcopenia. Amino acid supplementation, in the form of leucine has been shown to increase muscle protein synthesis and has been used to improve athletic performance. There had, therefore, been hope that this may be helpful is sarcopenia when assessed in two high quality studies. In these studies participants ingested 6 g or 15 g of leucine in an enriched diet for a 3-month period. This intervention alone did not improve muscle strength or functional capacity, however when combined with an exercise programme there was an improvement in muscle mass and strength, but not functional capacity.

HMB supplementation has been studied in sarcopenia combined with lysine and arginine, with exercise or on its own. In these studies participants received 2–3 g of HMB a day for between 8 and 24 weeks. HMB improved muscle mass in one study of participants on extended bed rest and muscle strength when combined with lysine and arginine. Eicosanoids, derived from unsaturated fatty acids, are considered one of the mediators and regulators of inflammation. It was therefore postulated that by changing the dietary intake of n-3 and n-6 long chain fatty acids could have an impact on inflammatory driven sarcopenia. Sadly, in the one study performed...
using α-linolenic acid a fatty acid supplement when combined with an exercise programme, no significant change was recorded in muscle mass or strength when compared with placebo.78

While the provision of oral or parenteral nutrition is vital and supported by national and international guidance in these patients, there are no consensus guidelines for nutritional supplementation in sarcopenia; this is an area of exciting future research.

Exercise
Resistance exercise, particularly progressive resistance exercise, has been shown to be the best current treatment available to improve muscle mass, strength and the functional capacity of older adults.79-81 Of five studies performed using resistance exercise alone, three reported an improvement in muscle mass and four reported an improvement in both muscle strength and the functional capacity of participants when compared with simple home exercises.79-83 These resistance training programmes have included free weights, weight machines, whole body vibration and elastic bands.84 This is supported by the 2009 Cochrane review which looked at 121 trials and concluded that resistance exercise resulted in improved muscle strength and function.83 Simple measures to increase physical activity have also been shown to decrease symptoms of frailty and improve muscle function.85 Although studies have shown a benefit of both exercise and resistance exercise, none have recruited participants based on their sarcopenic status, therefore the results cannot be directly translated to sarcopenia.20 Just being physically active may confer some beneficial effect on skeletal muscle health. A recent cross-sectional study of objectively measured physical activity in 32 men and 99 women suggested that all intensities of physical activity may be protective against sarcopenia.86

Pharmacological interventions
Pharmacological interventions for sarcopenia have focused on hormone replacement, particularly testosterone with conflicting results. An improvement in muscle mass can be achieved with testosterone replacement, however, this was not associated with an improvement functional capacity.87 88 Other treatments trialled include growth hormone supplementation which, while increasing muscle mass, was associated with an increase in adverse events.89 Ghrelin mimetics have been used to improve appetite and food intake which, in one study showed an improvement in stair climbing time and gait at 12 months.90 However, to date there are no drug treatments for sarcopenia although there is burgeoning research in this area paralleled by basic and molecular studies of skeletal muscle to identify key molecular pathways that can be targets for drug discovery.

CONCLUSIONS
Sarcopenia or muscle failure is an increasingly common condition that is associated with significant negative health outcomes. It is increasingly common in patients with gastrointestinal or liver disease, with significant clinical consequences. Sarcopenia is still poorly recognised by clinicians, in part due to the lack of a consensus definition. However, similar to malnutrition, it should become standard practice that we screen all patients for sarcopenia, using tools such as SARC-F screening tool, across a range of clinical settings. Furthermore, those identified as being at risk should be assessed by simple measures such as grip strength, which can be performed in the community or outpatient setting. Confirmation of sarcopenia can be achieved by measurement of ALM by DXA or alternatively use pre-existing abdominal imaging to calculate the L3 muscle index. Simple assessment and interventions, such as better recognition and malnutrition and nutritional supplementation can have a significant impact on the outcomes of patients. Physical activity is the cornerstone of sarcopenia management at present. Resistance exercise programmes combined with nutritional interventions show promise in the treatment of sarcopenia although more trials in sarcopenia are needed to provide a clear programme of treatment.

Twitter Thomas William Hollingworth @motilitydoc
Contributors TWH performed a literature search and wrote the article. SO contributed to the writing of this article. TRS and HP reviewed and edited the article.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Commissioned; externally peer reviewed.
ORCID iD
Thomas William Hollingworth http://orcid.org/0000-0003-3134-6648

REFERENCES
1 Shakespeare W. As you like it, 1623.
2 Sender R, Shai Fuchs RM. Revised estimates for the number of human and bacteria cells in the body RON. PLOS Biol 2013;14:1–21.
Small bowel and nutrition

38 Adams DW, Gurwara S, Silver HJ, et al. Sarcopenia is common in overweight patients with inflammatory bowel disease and may predict need for surgery. Inflamm Bowel Dis 2017;23:1182–6.
61 NICE Guide. Nutrition support for adults: or nutrition support for adults: oral or nutrition support, enteral nutrition support, enteral tube feeding at tube feeding and parenteral nutrition at nutrition your responsibility our responsibility, 2006.